Big Data From Alzheimer's Disease Whole Genome Sequencing Will Be Available To Researchers Due To Novel Global Research Database
BOSTON, July 12, 2013 /PRNewswire-USNewswire/ -- The Alzheimer's Association and the Brin Wojcicki Foundation announced today that massive amounts of new data have been generated by the first "Big Data" project for Alzheimer's disease. The data will be made freely available to researchers worldwide to quickly advance Alzheimer's science.
Discussed today at the Alzheimer's Association International Conference (AAIC) 2013 in Boston, the project obtained whole genome sequences on the largest cohort of individuals related to a single disease – more than 800 people enrolled in the Alzheimer's Disease Neuroimaging Initiative (ADNI).
The genome sequencing data – estimated to be 200 terabytes – will be housed in and available through the Global Alzheimer's Association Interactive Network (GAAIN), a planned massive network of Alzheimer's disease research data made available by the world's foremost Alzheimer's researchers from their own laboratories, and which also is being publicly announced today at AAIC 2013. GAAIN is funded by an initial $5 million dollar investment by the Alzheimer's Association, made possible due to the generous support of donors.
"The Alzheimer's Association is committed to creating open access to research data, and we believe GAAIN will transform how neuroscience data is shared and accessed by scientists throughout the world," said Maria Carrillo, Ph.D., Alzheimer's Association vice president of Medical and Scientific Relations. "By fostering a higher level of global data sharing, GAAIN will accelerate investigation and discovery in Alzheimer's through a system comparable to a search engine like Google or Bing for relevant data.""With the addition of more than 800 whole genomes on ADNI subjects that can be linked to the current rich dataset, ADNI data will be even more useful to scientists who are seeking new approaches to treatment and prevention of Alzheimer's disease," said Robert C. Green, M.D., M.P.H., of Brigham and Women's Hospital and Harvard Medical School, who led the ADNI sequencing project. "ADNI is a leader in open data sharing, having provided clinical, imaging and biomarker data to over 4,000 qualified scientists around the world, which has generated over 700 scientific manuscripts. First, Massive Whole Genome Sequencing Project in Alzheimer's Disease Whole genome sequencing determines all six billion letters in an individual's DNA in one comprehensive analysis. The raw data from the ADNI project is being made available to qualified scientists around the globe to mine for novel targets for risk assessment, new therapies, and much-needed insight into the causes of the fatal brain disease. The new data may enable scientists to better understand how our genes cause and are affected by bodily changes associated with Alzheimer's disease.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts